IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 5, 2011, Pages 413-416

  Vranic, Semir ^a,d   Gurjeva, Olga ^b   Frkovic Grazio, Snjezana ^c   Palazzo, Juan ^e   Tawfik, Ossama ^f   Gatalica, Zoran ^d  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b Ukrainian Strazhesko Institute   (Ukraine)

^c University Clinical Hospital Ljubljana   (Slovenia)

^d CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^f UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

adenoid cystic carcinoma; apocrine carcinoma; breast carcinoma; IMP3 protein; special types

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SOMATOMEDIN B;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; APOCRINE CARCINOMA; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; APOCRINE GLANDS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, ADENOID CYSTIC; CARCINOMA, DUCTAL, BREAST; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHENOTYPE; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80052764868     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182143399     Document Type: Article

References (27)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874. (Pubitemid 32878711)
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423. (Pubitemid 36842560)
4. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660-4671. (Pubitemid 41032603)
5. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994-4008. (Pubitemid 43990755)
6. Vranic S, Frkovic-Grazio S, Lamovec J, et al. Adenoid cystic carcinomas of the breast have low Topoisomerase IIa expression but frequently overexpress EGFR protein without EGFR gene amplification. Hum Pathol. 2010;41:1617-1623.
7. Foschini MP, Krausz T. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol. 2010; 27:77-90.
8. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract. 1997;193:753-758.
9. Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007;50:434-438. (Pubitemid 46328193)
10. Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24: 157-167.
11. Walter O, Prasad M, Lu S, et al. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol. 2009;40:1528-1533.
12. Sidoni A, Cartaginese F. IMP3 expression in triple-negative breast carcinoma. Hum Pathol. 2010;41:1355-1356.
13. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270. (Pubitemid 29046868)
14. Xu H. IMP3: a diagnostic and prognostic biomarker in malignant melanoma. Expert Rev Mol Diagn. 2008;8:557-558.
15. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517-18524. (Pubitemid 41389102)
16. Vikesaa J, Hansen TV, Jønson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006;25: 1456-1468.
17. Vranic S, Tawfik O, Palazzo J, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol. 2010;23:644-653.
18. Vranic S, Gatalica Z, Deng H, et al. ER-a36, a novel isoform of ERa66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol. 2011;64:54-57.
19. Kapoor S. IMP3: a new and important biomarker of systemic malignancies. Clin Cancer Res. 2008;14:5640.
20. Findeis-Hosey JJ, Yang Q, Spaulding BO, et al. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol. 2010;41:477-484.
21. Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol. 2011;42:303-314.
22. Arpino G, Clark GM, Mohsin S, et al. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer. 2002;94:2119-2127. (Pubitemid 34411967)
23. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374. (Pubitemid 39100473)
24. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141-150.
25. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9:R65.
26. Bhargava R, Beriwal S, Striebel JM, et al. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol. 2010;18:113-118.
27. Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444-455.